V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 20223849 | 20178536 | 1.6 | 101.9 | Palliative (P) | 2019-03-28 | 2019-04-12 | Trial Unspecified | 02 | N | CAPECITABINE + RT | 101439074 |
| 20223899 | 20178537 | 1.58 | 74 | Palliative (P) | 2018-02-09 | 2019-06-20 | Trial Unspecified | N | N | EOX | 101350599 |
| 20223978 | 20178538 | 1.55 | 103 | Curative (C) | 2018-01-25 | 2019-12-22 | Sorafenib | 02 | Y | SORAFENIB | 100936578 |
| 20224015 | 20178539 | 1.54 | 43.1 | Adjuvant (A) | 2018-10-03 | 2018-10-03 | EOX | 02 | N | CAPECITABINE + RT | 100839151 |
| 20224037 | 20178540 | 1.71 | 88.2 | null | 2018-05-23 | 2018-07-05 | EOX | 02 | N | CETUXIMAB + FLUOROURACIL + OXALIPLATIN | 101596662 |
| 20224087 | 20178541 | 1.51 | 59 | Palliative (P) | 2020-09-19 | 2020-10-02 | EOX | 02 | N | FLUOROURACIL + IRINOTECAN + PANITUMUMAB | 100971602 |
| 20224104 | 20178542 | 1.74 | 70 | Palliative (P) | 2018-07-27 | 2018-08-06 | EOX | 02 | Y | EOX | 101301210 |
| 20224360 | 20178543 | null | 64 | Palliative (P) | 2017-07-28 | 2017-08-01 | Sorafenib | 02 | N | SORAFENIB | 101589696 |
| 20224381 | 20178544 | 1.66 | 65 | Palliative (P) | 2016-12-06 | 2016-12-09 | CAPECITABINE + RT | N | null | CAPECITABINE + RT | 100311757 |
| 20224386 | 20178545 | 1.74 | 68.2 | Palliative (P) | 2019-06-15 | 2019-06-30 | Sorafenib | 02 | null | SORAFENIB | 100600064 |
| 20224447 | 20178546 | 1.87 | 80.5 | Palliative (P) | 2016-10-10 | 2016-10-10 | Sorafenib | 02 | N | SORAFENIB | 101077473 |
| 20224512 | 20178547 | 1.81 | 96 | null | 2018-06-06 | 2018-06-22 | IRINOTECAN + MDG + PANITUMUMAB | 02 | null | FLUOROURACIL + IRINOTECAN + PANITUMUMAB | 101619688 |
| 20224549 | 20178548 | 1.62 | 90.5 | Neo-adjuvant (N) | 2016-07-27 | 2016-08-17 | EOX | 02 | N | TRIAL | 100963001 |
| 20224650 | 20178549 | 1.62 | 46.9 | Palliative (P) | 2019-06-29 | 2019-06-30 | Cetuximab + FLUOROURACIL + OXALIPLATIN | 02 | N | CETUXIMAB + FLUOROURACIL + OXALIPLATIN | 101407602 |
| 20224653 | 20178550 | 1.82 | 90 | Neo-adjuvant (N) | 2018-04-12 | 2019-06-06 | EOX | 02 | N | EOX | 100633752 |
| 20224729 | 20178551 | 1.64 | null | null | 2017-11-30 | 2019-04-01 | Oxaliplatin + Raltitrexed | Y | null | OXALIPLATIN + RALTITREXED | 101570767 |
| 20224734 | 20178552 | 1.7 | 85.4 | Palliative (P) | 2021-02-24 | 2021-02-24 | IRINOTECAN + MDG + PANITUMUMAB | 02 | N | FLUOROURACIL + IRINOTECAN + PANITUMUMAB | 100902920 |
| 20224756 | 20178553 | 1.53 | 102 | Palliative (P) | 2018-08-15 | 2019-06-06 | EOX | N | N | CAPECITABINE + RT | 101464262 |
| 20224768 | 20178554 | 1.71 | 73.4 | Palliative (P) | 2017-04-08 | 2017-04-22 | EOX | N | N | CETUXIMAB + IRINOTECAN + MDG | 100177448 |
| 20224857 | 20178555 | 1.7 | 101.3 | Curative (C) | 2018-09-07 | 2018-09-14 | EOX | 02 | N | CETUXIMAB + FLUOROURACIL + OXALIPLATIN | 100499662 |
| 20224935 | 20178556 | 1.58 | 75.6 | Palliative (P) | 2016-08-05 | 2016-08-12 | EOX | 02 | N | FLUOROURACIL + IRINOTECAN + PANITUMUMAB | 100659852 |
| 20224959 | 20178557 | 0 | 60.4 | Neo-adjuvant (N) | null | 2018-09-06 | Cetuximab + FLUOROURACIL + OXALIPLATIN | 02 | N | CETUXIMAB + FLUOROURACIL + OXALIPLATIN | 101029100 |
| 20225173 | 20178558 | null | 80.4 | null | 2019-08-24 | 2019-09-13 | EOX | 02 | null | FLUOROURACIL + IRINOTECAN + PANITUMUMAB | 101728732 |
| 20225562 | 20178559 | 1.71 | 80 | Palliative (P) | 2017-05-09 | 2017-05-23 | Cetuximab + FOLFIRI cycle 2 onwards | 1 | N | TRIAL | 100346891 |
| 20000735 | 20178560 | 1.78 | 0 | null | null | 2021-11-10 | Sorafenib | 02 | null | SORAFENIB | 100854971 |
| 20001010 | 20178561 | 1.83 | 154 | null | 2019-01-25 | 2019-05-26 | EOX | 02 | N | EOX | 101744577 |
| 20001746 | 20178562 | 1.67 | 50.4 | Palliative (P) | 2019-06-17 | 2019-08-10 | Cetuximab + FLUOROURACIL + OXALIPLATIN | 02 | N | CETUXIMAB + FLUOROURACIL + OXALIPLATIN | 100062213 |
| 20002481 | 20178563 | 1.59 | null | Palliative (P) | 2021-03-31 | 2021-03-31 | Trial Unspecified | 02 | null | EOX | 101721790 |
| 20002961 | 20178564 | 1.85 | 72.8 | Palliative (P) | 2018-04-21 | 2018-05-01 | Cetuximab + Oxaliplatin + MdG Maint | 02 | N | CETUXIMAB + FLUOROURACIL + OXALIPLATIN | 101812293 |
| 20004034 | 20178566 | 1.75 | 69.4 | null | 2021-05-05 | 2021-06-02 | EOX | 02 | null | EOX | 100599996 |
| 20004464 | 20178567 | 1.57 | 104.4 | Adjuvant (A) | 2021-03-19 | 2021-08-25 | Oxaliplatin + Raltitrexed | 02 | N | OXALIPLATIN + RALTITREXED | 101744780 |
| 20007278 | 20178569 | 1.74 | 41.7 | Palliative (P) | 2017-07-03 | 2017-12-27 | Sorafenib | 02 | N | SORAFENIB | 100701057 |
| 20007416 | 20178570 | 1.83 | 64.1 | Palliative (P) | 2017-11-17 | 2017-11-18 | IRINOTECAN + MDG + PANITUMUMAB | 02 | N | FLUOROURACIL + IRINOTECAN + PANITUMUMAB | 101774181 |
| 20007469 | 20178571 | 1.69 | 101 | Palliative (P) | 2021-09-03 | 2021-09-03 | EOX | 02 | N | CAPECITABINE + RT | 100543302 |
| 20007859 | 20178572 | 1.48 | 71.8 | Adjuvant (A) | 2017-07-24 | 2017-08-23 | EOX | 02 | N | CETUXIMAB + FLUOROURACIL + OXALIPLATIN | 101240520 |
| 20007934 | 20178573 | 1.85 | 60 | Neo-adjuvant (N) | 2015-11-27 | 2018-01-02 | CAPECITABINE + RT | 02 | N | CAPECITABINE + RT | 100324232 |
| 20010911 | 20178575 | 1.74 | 67 | Palliative (P) | 2018-03-17 | 2019-10-11 | Sorafenib | 02 | N | SORAFENIB | 101340964 |
| 20011473 | 20178576 | 1.7 | 65.7 | Palliative (P) | 2020-07-31 | 2021-02-24 | Panitumumab + Irinotecan + MdG | N | Y | FLUOROURACIL + IRINOTECAN + PANITUMUMAB | 100269900 |
| 20011580 | 20178577 | 1.79 | 105 | Curative (C) | 2017-04-24 | 2017-04-24 | EOX | 02 | N | OXALIPLATIN + RALTITREXED | 100325417 |
| 20011920 | 20178578 | 1.59 | 89.3 | Palliative (P) | 2018-04-15 | 2018-07-23 | Trial Unspecified | 02 | N | TRIAL | 100375811 |
| 20013213 | 20178579 | 1.74 | 59.8 | null | 2020-06-24 | 2020-06-25 | Sorafenib | 02 | null | SORAFENIB | 101845907 |
| 20013346 | 20178581 | 1.67 | 69.2 | Curative (C) | 2021-04-01 | 2021-04-30 | Sorafenib | 02 | N | SORAFENIB | 100553413 |
| 20013573 | 20178582 | 1.88 | 60.5 | Palliative (P) | 2020-10-22 | 2020-11-06 | EOX | 02 | N | CETUXIMAB + FLUOROURACIL + OXALIPLATIN | 100579573 |
| 20013935 | 20178583 | 1.72 | 72 | null | 2018-03-18 | 2018-04-12 | Trial Unspecified | null | null | TRIAL | 101349825 |
| 20017133 | 20178586 | 1.68 | 94.2 | null | null | 2019-05-01 | Fluorouracil+Mitomycin+RT (Anal Ca) | 02 | null | FLUOROURACIL + MITOMYCIN | 101609787 |
| 20018256 | 20178588 | 0 | 80.3 | Palliative (P) | null | 2021-04-23 | LENVATINIB | 99 | N | LENVATINIB | 101552283 |
| 20018460 | 20178589 | 1.63 | 65.5 | Curative (C) | null | 2020-04-25 | HCX (Cape + Cisp + Tras) - Load | 02 | N | HCX | 100738134 |
| 20018846 | 20178591 | null | null | null | null | 2018-03-24 | LANREOTIDE | null | N | LANREOTIDE | 101666273 |
| 20018951 | 20178592 | null | null | Palliative (P) | null | 2018-12-24 | null | 02 | N | FLUOROURACIL + OXALIPLATIN + PANITUMUMAB | 101044645 |
| 20022145 | 20178593 | 1.73 | 64.6 | null | 2020-05-07 | 2020-05-29 | null | null | null | HCX | 101355962 |